Zuplenz Patent Expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8580830 AQUESTIVE Non-mucoadhesive film dosage forms
Nov, 2029

(5 years from now)

US9095577 AQUESTIVE Stabilized amine-containing actives in oral film compositions
Jul, 2030

(5 years from now)

Zuplenz is a drug owned by Aquestive Therapeutics Inc. Zuplenz uses Ondansetron as an active ingredient. Zuplenz was launched by Aquestive in 2010. It is is available in film form for oral use. Its generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 13, 2030 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ONDANSETRON ingredient

Market Authorisation Date: 02 July, 2010

Treatment: NA

Dosage: FILM

More Information on Dosage

ZUPLENZ family patents

Family Patents